Biotech companies targeting rare diseases often lack the scale for in-house manufacturing or testing. US, NY, UNITED STATES, April 21, 2025 /E ...

The global drug discovery services market is projected to grow at a CAGR of 15% from 2025 to 2030. This growth is driven by ...

The Orphan Therapeutics Accelerator (OTXL), a non-profit biotech organization focused on completing development and ...

Clinical-stage company targeting fundamental drivers of inflammation, autoimmunity and fibrosis, founded by Versant Ventures and Novartis Venture Fund- ...

The sector has grown from its early days of molecule discoveries into an ecosystem that includes biotech, medical devices, ...

The human microbiome market is projected to grow at a CAGR of 31% over the forecast period. Major factors driving growth ...

Medical equipment maker Thermo Fisher Scientific on Wednesday cut its annual profit forecast, in anticipation of a potential ...

Wilson Community College is building a biotechnology and workforce center to prepare students for jobs in the biotech ...

Siren said proceeds will go toward investigational new drug (IND)-enabling animal studies and clinical-grade production of therapy. Upon FDA approval of an IND application, Siren plans to start on ...

How CDMOs are reshaping pharmaceutical partnerships through friendshoring, risk-sharing economics, and specialized development capabilities.